Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Your Profile Become a Member/Get Newsletter Contact Us
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by NARSAD, the Brain and Behavior Research Fund, and was created with funding from the U.S. National Institute of Mental Health.
Printable version  
SZGene - Gene overview of all published SZ-association studies for COMT    
Back Search Methods Disclaimer Credits
 Gene: COMT   Entrez Gene    View on AlzGene   View on MSGene   View on PDGene
 Protein: catechol-O-methyltransferase   ProteinLink
 Chromosome: 22   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 21 October 2010
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      SZ Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Anttila, 2004
Overlaps with
Illi, 2003
CL  1  (detail)  94
(51%)
IV--98
(-)
-n.a.
Costas, 2010
Spain (Valencia) CL  1  (detail)  371
(35%)
IV--417
(37%)
-Negative
Costas, 2010
Spain (Santiago de Compostela) CL  1  (detail)  391
(33%)
IV--625
(47%)
-Positive
Daniels, 1996
UK, Ireland CL  1  (detail)  78
(35%)
IIIR-44.3 + 13.5
(-)
78
(35%)
44 + 12.2
(-)
Negative
de Chaldee, 1999
France CL  4  (detail)  143
(29%)
IIIR-40 + 12.9
(-)
191
(44%)
49 + 10
(-)
Positive
Dutt, 2009
UK, Ireland CL  1  (detail)  83
(-)
IV--57
(-)
-Negative
Egan, 2001
USA (CBDB) CL  1  (detail)  175
(21%)
IV-36.1 + 8.5
(18-60)
55
(58%)
33.9 + 9.2
(18-60)
Positive
Eisenberg, 2009
USA CL  1  (detail)  25
(24%)
IV-27.5 + 6.2
(18-43)
47
(30%)
28.7 + 7.5
(20-50)
n.a.
Funke, 2005
USA CL  4  (detail)  196
(-)
IV--467
(52%)
39.3
(-)
Positive
Galderisi, 2005
Italy CL  1  (detail)  106
(28%)
IV--111
(-)
-Negative
Gallinat, 2003
Germany CL  1  (detail)  49
(24%)
IV-32.8 + 9.3
(-)
170
(50%)
43.9 + 14.9
(-)
Negative
Goghari, 2007
USA CL  1  (detail)  41
(22%)
IV-45.2 + 10.7
(-)
20
(115%)
48.1 + 15.1
(-)
Negative
Goldberg, 2003
Overlaps with
Egan, 2001
CL  1  (detail)  74
(41%)
IV-37 + 8
(-)
68
(59%)
-n.a.
Golimbet, 2006
Russia CL  1  (detail)  124
(49%)
1023.9 + 8.3
(-)
34.5 + 12.9
(-)
116
(58%)
32.2 + 12.9
(-)
Negative
Haraldsson, 2008
Iceland CL  1  (detail)  112
(28%)
U-41 + 9.9
(-)
97
(36%)
40.6 + 9.3
(-)
Negative
Haraldsson, 2009
Overlaps with
Haraldsson, 2008
CL  1  (detail)  110
(28%)
M-41 + 10
(-)
96
(36%)
41 + 9
(-)
n.a.
Herken, 2001
Overlaps with
Herken, 2003a
CL  1  (detail)  129
(33%)
IV-34.3 + 9.9
(-)
65
(34%)
30.7 + 6.3
(-)
n.a.
Herken, 2003a
Turkey CL  1  (detail)  143
(35%)
IV-32.3 + 9.1
(-)
79
(-)
-Negative
Ho, 2005
USA CL  1  (detail)  159
(26%)
M-26.5 + 7.3
(-)
84
(60%)
27 + 7
(-)
Negative
Hoenicka, 2009
Spain CL  2  (detail)  337
(33%)
IV22.8 + 6.3
(-)
-285
(40%)
-Positive
Hoenicka, 2010
Overlaps with
Hoenicka, 2009
CL  1  (detail)  337
(33%)
IV--364
(53%)
-n.a.
Hoogendoorn, 2005
Netherlands CL  1  (detail)  208
(-)
IV--288
(-)
-Negative
Horowitz, 2005
Israel (I) CL  5  (detail)  190
(41%)
U--188
(41%)
-Negative
Horowitz, 2005
Israel (II) CL  3  (detail)  535
(38%)
U--567
(39%)
-Negative
Horowitz, 2005
Overlaps with
Horowitz, 2005 Israel (II)
CL  3  (detail)  190
(41%)
U--188
(41%)
-n.a.
Illi, 2003
Finland CL  1  (detail)  94
(51%)
IV--94
(50%)
-Negative
Jones, 2001
Overlaps with
Norton, 2002
CL  1  (detail)  180
(24%)
IV--173
(-)
-n.a.
Joober, 2002
Canada CL  1  (detail)  104
(-)
IV--96
(-)
-Negative
Karayiorgou, 1998
USA CL  5  (detail)  157
(32%)
IIIR--129
(-)
-Negative
Kotler, 1999
Israel CL  1  (detail)  92
(37%)
10--415
(62%)
28 + 15
(-)
Negative
Krabbendam, 2006
Spain CL  1  (detail)  23
(30%)
IV-36 + 10.5
(-)
21
(57%)
38.3 + 15.6
(-)
Negative
Martorell, 2007
Spain CL  11  (detail)  585
(34%)
IV-48.8 + 17.5
(-)
615
(48%)
43.1 + 15.3
(-)
Negative
Mas, 2009
Spain CL  4  (detail)  159
(-)
IV--373
(54%)
51.9 + 19
(-)
Negative
Muntjewerff, 2007
Netherlands CL  1  (detail)  252
(27%)
IV-41 + 14
(-)
405
(59%)
51 + 13
(-)
Negative
Nicodemus, 2006
Germany CL  3  (detail)  501
(35%)
IV--627
(52%)
-Positive
Nicodemus, 2006
USA CL  3  (detail)  296
(21%)
IV--370
(51%)
-Positive
Nieratschker, 2010
Overlaps with
Strohmaier, 2010
CL  13  (detail)  631
(45%)
IV-38.5 + 11.7
(-)
776
(43%)
45.5 + 13.5
(-)
n.a.
Norton, 2002
Overlaps with
Williams, 2005
CL  1  (detail)  346
(28%)
IV-46 + 13
(-)
334
(29%)
43 + 12
(-)
n.a.
Norton, 2002
UK CL  1  (detail)  346
(28%)
IV-46 + 13
(-)
334
(29%)
43 + 12
(-)
Negative
Pal, 2009
Croatia CL  11  (detail)  103
(42%)
10-43.6 + 10.6
(23-74)
131
(-)
50.3 + 7.5
(30-74)
Positive
Pomarol-Clotet, 2010
Overlaps with
Hoenicka, 2009
CL  1  (detail)  42
(26%)
IV20
(-)
39.8 + 10
(23-63)
31
(35%)
35.8 + 14.2
(20-58)
n.a.
Poyurovsky, 2005
Israel CL  1  (detail)  113
(28%)
IV--171
(56%)
-Negative
Prata, 2009a
UK CL  1  (detail)  42
(17%)
IV-35.5 + 11.4
(-)
48
(52%)
34.1 + 10.7
(-)
Positive
Prata, 2009b
Overlaps with
Prata, 2009a
CL  1  (detail)  41
(-)
IV--44
(-)
-n.a.
Rosa, 2010
Overlaps with
Sanders, 2008 (USA-NIMH)
CL  1  (detail)  67
(21%)
IV-34 + 9.8
(-)
168
(57%)
36 + 10.8
(-)
n.a.
Rujescu, 2003
Germany CL  1  (detail)  28
(-)
U--328
(55%)
46 + 15
(19-79)
Negative
Rybakowski, 2002
Poland CL  1  (detail)  117
(37%)
M-30
(18-63)
60
(52%)
27
(22-60)
Negative
Sanders, 2008
USA, Australia CL  29  (detail)  1870
(31%)
IV--2002
(53%)
-Negative
Sazci, 2004
Turkey CL  1  (detail)  297
(43%)
IV-41.2 + 9.4
(-)
341
(44%)
40.9 + 8.1
(-)
Positive
Shaikh, 2010
Overlaps with
Dutt, 2009
CL  1  (detail)  70
(-)
IV--204
(63%)
40.1 + 13.2
(18-65)
n.a.
Shifman, 2002
Israel (I) CL  1  (detail)  720
(36%)
IV--2970
(24%)
-Positive
Shifman, 2002
Israel (II) CL  1  (detail)  724
(36%)
IV--4899
(28%)
-Positive
Shifman, 2002
Israel (III) CL  1  (detail)  714
(35%)
IV--2849
(24%)
-Positive
Straub, 2007
Overlaps with
Egan, 2001
CL  2  (detail)  309
(21%)
IV--317
(49%)
-n.a.
Strohmaier, 2010
Germany CL  14  (detail)  634
(45%)
IV-38.5 + 11.7
(-)
776
(43%)
45.5 + 13.5
(-)
Negative
Strous, 1997
USA CL  1  (detail)  54
(-)
IIIR--87
(-)
-Negative
Szoke, 2006
France CL  1  (detail)  66
(35%)
IV-34.1 + 8.9
(18-60)
50
(48%)
42.2 + 12.9
(18-60)
Negative
Talkowski, 2008
USA CL  15  (detail)  478
(-)
IV--501
(-)
-Positive
Talkowski, 2008
Overlaps with
Talkowski, 2008
CL  5  (detail)  328
(-)
IV--501
(-)
-n.a.
Williams, 2005
UK CL  3  (detail)  709
(-)
IV--710
(69%)
-Negative
Wirgenes, 2010
Norway CL  15  (detail)  171
(46%)
IV-33.7 + 9.6
(-)
340
(50%)
34.9 + 10.1
(-)
Positive
Wonodi, 2006
Overlaps with
Wonodi, 2003
CL  1  (detail)  86
(34%)
IV--50
(44%)
-n.a.
Zumarraga, 2010
Spain CL  1  (detail)  44
(48%)
IV-35 + 11
(-)
96
(63%)
44 + 10
(19-65)
Negative
 Asian
Arinami, 2001
Japan CL  1  (detail)  300
(44%)
IIIR22.6
(12-39)
44.3
(19-78)
300
(45%)
47.8
(29-75)
Negative
Chen, 1996
Overlaps with
Chen, 1999
CL  1  (detail)  177
(46%)
IIIR-47
(-)
99
(45%)
45
(-)
n.a.
Chen, 1997
Overlaps with
Chen, 1999
CL  1  (detail)  177
(46%)
IIIR-47
(-)
99
(45%)
45
(-)
n.a.
Chen, 1997
Taiwan CL  1  (detail)  177
(46%)
IIIR-47
(-)
99
(45%)
45
(-)
Negative
Chen, 1999
Taiwan CL  4  (detail)  177
(46%)
IV-47 + 6
(-)
99
(45%)
45 + 5
(-)
Negative
Chien, 2009
Taiwan CL  3  (detail)  124
(43%)
IV21.9 + 5.5
(-)
37.5 + 6.8
(-)
112
(62%)
31.8 + 7.6
(-)
Negative
Fan, 2005
China CL  1  (detail)  862
(43%)
IIIR-39.8 + 12
(-)
928
(40%)
38.3 + 11.7
(-)
Negative
Han, 2004
Korea CL  1  (detail)  168
(0%)
IV--158
(0%)
-Negative
Han, 2006
Korea CL  1  (detail)  132
(0%)
IV--80
(0%)
-Negative
Inada, 2003
Japan CL  1  (detail)  100
(-)
IIIR--201
(-)
-Negative
Iwata, 2003
Japan CL  1  (detail)  51
(57%)
IV13.5 + 1.7
(9-16)
20 + 7
(-)
148
(56%)
21 + 7
(-)
Negative
Joo, 2005
Korea CL  1  (detail)  239
(38%)
IV-33.3 + 8.1
(-)
248
(43%)
23.9 + 6.7
(-)
Negative
Kang, 2010
China CL  1  (detail)  287
(44%)
IV24.3
(-)
27.8 + 3.1
(-)
84
(54%)
26.6 + 2.9
(-)
Negative
Kim, 2008
Korea CL  1  (detail)  165
(42%)
IV24.5 + 6.9
(-)
38.4 + 10.1
(-)
415
(40%)
24.5 + 5.7
(19-57)
Negative
Lee, 2005
Korea CL  5  (detail)  320
(52%)
IV-32.6 + 10
(-)
379
(51%)
40.1 + 14
(-)
Positive
Liou, 2001
Taiwan CL  1  (detail)  198
(53%)
IV-37.8 + 12.1
(-)
188
(48%)
38.6 + 16.6
(-)
Negative
Numata, 2006
Japan CL  1  (detail)  159
(28%)
IV25.9 + 8.3
(-)
53.9 + 12.8
(-)
317
(-)
-Negative
Nunokawa, 2007
Japan CL  5  (detail)  399
(47%)
IV23.1 + 7.2
(-)
40.6 + 14.7
(-)
440
(48%)
38 + 10.4
(-)
Negative
Ohmori, 1998
Japan CL  1  (detail)  150
(57%)
IV-54 + 11.5
(-)
150
(50%)
55 + 6.8
(-)
Positive
Ohnishi, 2006
Japan CL  1  (detail)  47
(-)
IV--76
(-)
-Negative
Park, 2002
Korea CL  1  (detail)  103
(39%)
IV-42.1 + 8.1
(-)
103
(-)
-Positive
Park, 2009
Korea CL  6  (detail)  354
(50%)
IV-44 + 9.3
(23-76)
396
(43%)
54.6 + 9.3
(28-80)
Positive
Sun, 2005
China CL  2  (detail)  82
(-)
10--108
(-)
-Positive
Wang, 2009
China CL  14  (detail)  540
(45%)
IV--660
(46%)
-Positive
Yu, 2007
China CL  3  (detail)  241
(46%)
IV--290
(45%)
-Negative
 Other/Mixed
Ehrlich, 2009
USA CL  1  (detail)  98
(26%)
IV-35.1 + 10.8
(-)
114
(39%)
32.1 + 11.1
(-)
n.a.
Gupta, 2009
India CL  7  (detail)  254
(39%)
IV-29.2 + 7.6
(-)
225
(62%)
86 + 31
(-)
Positive
Kremer, 2003
Palestine CL  1  (detail)  276
(69%)
IV21 + 4.8
(-)
34.8 + 13.6
(-)
77
(69%)
39.5 + 15.5
(-)
Positive
Roffman, 2008
Overlaps with
Ehrlich, 2009
CL  1  (detail)  79
(-)
IV--75
(-)
-n.a.
Semwal, 2002
India CL  1  (detail)  536
(44%)
IV-22.8 + 7
(-)
936
(47%)
32.9 + 12.7
(-)
Negative
Srivastava, 2010
Overlaps with
Semwal, 2002
CL  5  (detail)  215
(48%)
IV21.4 + 6.1
(-)
29.3 + 8.9
(-)
215
(40%)
34.6 + 12.4
(-)
Positive
Thaker, 2004
USA CL  1  (detail)  62
(-)
U-41 + 10
(-)
53
(-)
41 + 15
(-)
Negative
Wonodi, 2003
USA CL  1  (detail)  96
(32%)
IV-43.2 + 10.7
(-)
79
(43%)
42.5 + 15.9
(-)
Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Chen, 2004
Ireland (ISHDSF)  3  (detail)  267515
(-)
IIIR--822
(-)
-Positive
Egan, 2001
Overlaps with
Egan, 2001 (CC)
 1  (detail)   175
(-)
IV--219
(-)
-Positive
Fallin, 2005
USA  7  (detail)  263274
(26%)
IV19.5 + 4.5
(-)
-548
(50%)
-Negative
Glaser, 2006
Bulgaria  1  (detail)  488488
(46%)
M-33 + 8
(-)
976
(50%)
59.5 + 9
(-)
Negative
Goldberg, 2003
Overlaps with
Egan, 2001 (CC)
 1  (detail)  74-IV----n.a.
Handoko, 2005
Australia  4  (detail)  50107
(-)
IV----Positive
McClay, 2006
Overlaps with
Chen, 2004
 1  (detail)  268-U----n.a.
Nieratschker, 2010
Overlaps with
Strohmaier, 2010
 13  (detail)  207207
(37%)
IV-29.6 + 7.5
(-)
--n.a.
Shaikh, 2010
Overlaps with
Dutt, 2009
 1  (detail)   138
(40%)
IV-40.8 + 11.8
(21-65)
109
(53%)
45.9 + 12.8
(19-65)
Negative
Straub, 2007
Overlaps with
Egan, 2001
 2  (detail)  269309
(21%)
IV--372
(58%)
-n.a.
Strohmaier, 2010
Germany  14  (detail)  180-IV----Negative
Talkowski, 2008
Bulgaria  16  (detail)  659659
(50%)
IV--1318
(50%)
-Negative
Talkowski, 2008
USA  6  (detail)  150150
(50%)
IV--300
(50%)
-Positive
Wei, 1999
UK  2  (detail)  4949
(41%)
U--98
(50%)
-Negative
Williams, 2005
Bulgaria  3  (detail)  488488
(-)
IV--976
(50%)
-Negative
 Asian
Chien, 2009
Taiwan  3  (detail)  83-IV22.4 + 6.3
(-)
---Positive
Fan, 2002
China  5  (detail)  166166
(39%)
IIIR--332
(50%)
-Negative
Li, 1996
China  1  (detail)  178178
(36%)
IIIR-26.7 + 6.6
(15-49)
356
(50%)
-Trend
Li, 2000
China  7  (detail)  198198
(39%)
M-26.7 + 6.7
(15-49)
396
(50%)
-Positive
Liao, 2009
Taiwan  3  (detail)  212251
(-)
IV--429
(-)
-Positive
Semwal, 2001
Overlaps with
Semwal, 2002
 1  (detail)  179179
(42%)
IV22.1 + 6.3
(-)
-358
(50%)
-n.a.
Tsai, 2006
China  1  (detail)  220220
(41%)
IV-30.3 + 8.2
(-)
440
(50%)
-Negative
 Other/Mixed
Kremer, 2003
Overlaps with
Kremer, 2003
 1  (detail)  248276
(69%)
IV21 + 4.8
(-)
34.8 + 13.6
(-)
--n.a.
Kunugi, 1997
UK, Japan  2  (detail)  2276
(-)
U----Negative
Liu, 2002a
Overlaps with
Liu, 2002b USA (II)
 1  (detail)  2626
(-)
IV10.1 + 1.8
(-)
-52
(50%)
-n.a.
Liu, 2002a
USA (I)  2  (detail)  107107
(-)
IV--214
(50%)
-Negative
Liu, 2002a
USA (II)  2  (detail)  2626
(-)
IV10.1 + 1.8
(-)
-52
(50%)
-Negative
Liu, 2002a
Overlaps with
Liu, 2002b USA (I)
 1  (detail)  107107
(-)
IV--214
(50%)
-n.a.
Liu, 2002b
USA (I)  1  (detail)  107107
(-)
IV--214
(50%)
-Positive
Liu, 2002b
USA (II)  1  (detail)  2626
(-)
IV10.1 + 1.8
(-)
-52
(50%)
-Positive
Sanders, 2005
USA  5  (detail)  136136
(48%)
IIIR20
(5-45)
-510
(-)
-Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine SZ diagnosis ->  "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Research Participants
Collaborators
Copyright © 2005-2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright